ADXN
Addex Therapeutics Ltd
There isn't enough reported data to score ADXN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ADXN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ADXN's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ADXN PE Valuation
ADXN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ADXN Forward outlook
There aren't enough analyst estimates for ADXN to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ADXN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.75 | +$2.35 |
| Q1 2026 | -$8.20 | -165% |
| Q4 2025 | -$8.92 | -188% |
| Q3 2025 | -$8.85 | -216% |
| Q2 2025 | -$9.10 | -283% |
| Q1 2025 | $12.57 | +$31.74 |
| Q4 2024 | $10.16 | +$30.43 |
| Q3 2024 | $7.61 | +$32.39 |
ADXN is still losing money, but far less than before: $6.75 per share over the past year, against $88.12 at its worst in early 2020.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ADXN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.9K | -73% |
| Q4 2025 | $299 | -84% |
| Q3 2025 | $35.8K | -45% |
| Q2 2025 | $43.8K | -68% |
| Q4 2024 | $1.8K | -99% |
| Q3 2024 | $64.8K | -84% |
| Q2 2024 | $138.8K | -82% |
| Q1 2024 | $281.1K | -53% |
ADXN's revenue has slid since its 2020 peak: $11,928 last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6484% | -4470 points |
| Q1 2026 | -6239% | N/A |
| Q4 2025 | -314219% | -284668 points |
| Q3 2025 | -2342% | -1186 points |
| Q2 2025 | -2015% | -1235 points |
| Q4 2024 | -29551% | -27803 points |
| Q3 2024 | -1156% | -927 points |
| Q2 2024 | -780% | -717 points |
ADXN's operating margin was −6484% last quarter, down 4470 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ADXN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ADXN on profitability, with a higher operating margin.
ADXN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$564.2K | -$58.8K |
| Q1 2026 | -$922K | -$201.2K |
| Q4 2025 | -$732.4K | -$704.1K |
| Q3 2025 | -$641.9K | -$160.5K |
| Q2 2025 | -$505.4K | +$2.8M |
| Q1 2025 | -$720.8K | +$1.9M |
| Q4 2024 | -$28.4K | +$723.1K |
| Q3 2024 | -$481.4K | +$2.2M |
ADXN has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ADXN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADXN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +27K shares |
| 1 year | +90% | +687K shares |
| 3 years | +142% | +852K shares |
| 5 years | +412% | +1.2M shares |
| Available history | +559% | +1.2M shares |
ADXN has 1M diluted shares, up 90% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1,516 |
| Q1 2026 | $3,829 |
| Q4 2025 | — |
| Q3 2025 | $3,306 |
| Q2 2025 | $31,176 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ADXN spent $8,651 buying back its own shares over the past year, down 72% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ADXN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ADXN Net Leverage
ADXN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ADXN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.0 | Neutral |
ADXN's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ADXN PE vs Healthcare Sector
| Metric | ADXN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ADXN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ADXN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.37 | 57% above |
| 20 week MA | $4.35 | 22% above |
| 50 week MA | $5.99 | 12% below |
| 100 week MA | $7.17 | 26% below |
| 200 week MA | $9.61 | 45% below |
ADXN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ADXN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $226.0 | $483.8 | +114% |
| 2021 | $483.8 | $132.6 | -73% |
| 2022 | $132.6 | $11.2 | -92% |
| 2023 | $11.2 | $6.05 | -46% |
| 2024 | $6.05 | $7.52 | +24% |
| 2025 | $7.52 | $7.99 | +6.3% |
| 2026 YTD | $7.99 | $5.29 | -34% |
ADXN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.